SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is buzzing with community excitement driven by its unique blend of meme culture and real-world utility, notably through its CockyWings LLC chicken wing business. Discussions among "the Flock" highlight multiple revenue streams, passive income opportunities from liquid staking, and the new Memes Hub DAPP, all contributing to a bullish outlook for this prominent Cardano meme asset. This active engagement around its innovative approach and growth potential keeps it trending.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as crypto enthusiasts actively anticipate the beginning of a new yearly candle, sparking widespread discussion about its long-term potential. Community sentiment is largely bullish, with many analyzing historical chart patterns and LTC's established role as "digital silver," fueling expectations of significant appreciation in the coming cycle. Despite some bearish views, many investors are focused on dollar-cost averaging and long-term holding.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp is trending with immense community speculation surrounding a potential SPAC merger, driving significant discussion around its notably low float and high insider ownership. Traders are actively comparing its recent massive volume spikes and trading halts to other high-flying SPACs, anticipating substantial upside.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending amid recent leadership changes, including its CFO stepping down and the appointment of a new board member with M&A experience, fueling widespread community speculation about a potential acquisition. This comes as the company navigates a mixed market reaction to a partial summary judgment in a key lawsuit and expands global access to MIPLYFFA through a new international distribution agreement. High institutional ownership continues to underscore the perceived long-term value despite recent stock volatility and varied sentiment among investors.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending after a notable price surge, sparking debate among the community regarding its volatility and potential for sustained growth. Investors are actively discussing the token's real-world utility through the Flexa network and ongoing partnerships, yet many express frustration over its historical price performance. Speculation about significant developments, including potential mergers or major platform announcements, fuels both cautious optimism and skepticism.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines, Inc.

Unusual Machines is trending due to heightened expectations for its US-made drone components, fueled by anticipated restrictions on foreign-produced parts and recent positive financial performance. Community discussions emphasize UMAC's strategic role in providing NDAA-compliant solutions for growing defense programs, including large-scale government initiatives. This positioning is seen as critical for strengthening the domestic drone supply chain within a rapidly expanding sector.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings (CELH) is trending significantly following J.P. Morgan's inclusion as a top pick for 2026, bolstered by robust retail sales growth and strategic brand integration with PepsiCo. The community is actively debating its potential for substantial appreciation into 2026, frequently contrasting bullish long-term outlooks with frustrations over perceived short-term market manipulation and resistance levels. This dynamic highlights both strong underlying business fundamentals in the energy drink sector and ongoing volatility as the company continues its expansion.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amid a mixed community reaction to its holiday giveaway, where users are actively discussing receiving minimal crypto rewards or experiencing app glitches while hoping for bigger prizes like a Porsche. This coincides with recent downward pressure on the stock and cautious outlooks from some analysts pointing to expected weakness in crypto trading volumes, despite the platform's broader expansion efforts.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending following its recent inclusion in the S&P 500, a move that sparked intense debate over institutional buying and market manipulation. Community discussion is highly polarized, with many expressing strong bearish sentiment, labeling the company a 'scam' due to its aggressive subprime lending model, perceived overvaluation, and insider activity. Meanwhile, a contingent of bulls maintains optimism for its turnaround story, even as an ongoing securities fraud lawsuit with accelerated discovery deadlines adds to the volatility and scrutiny.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is trending amid intense community discussion, largely fueled by the burgeoning meme coin "$COCK" which is generating buzz with claims of real-world utility and on-chain liquidity. This viral activity, however, is juxtaposed with widespread frustration and deep skepticism among many Cardano holders, who are lamenting recent price action, calling the asset a "scam," and directing pointed criticism at its founder. The polarized sentiment reflects a market grappling with significant dips and constant comparisons to other altcoins, leaving many questioning ADA's near-term outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Update

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA - Get Free Report) was the target of a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling...

MIRA Pharmaceuticals (NASDAQ:MIRA) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of MIRA Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday...

Shares of Mira Pharmaceuticals surged 70% after-hours on Wednesday after the company announced new preclinical data showing its oral drug candidate Mira-55 outperformed injected morphine in normalizing pain and reducing inflammation in an animal model of chronic inflammatory pain.The study, conducted as part of Mira’s Mira-55 program, found that the orally administered compound not only restored pain thresholds to baseline levels but also demonstrated strong anti-inflammatory effects, pointing to a dual action that morphine failed to match.&nbsp;The company said these findings will support its planned Investigational New Drug (IND) application for chronic inflammatory pain and reinforce its position in the $70 billion non-opioid pain market.Mira-55, a non-psychotropic marijuana analog, achieved full pain normalization and significantly reduced paw swelling, confirming a CB2 receptor-mediated anti-inflammatory mechanism. Morphine, by contrast, showed only partial inflammation reduction through indirect effects on the central nervous system.The company noted that this is the first study in the program to measure inflammation directly alongside pain. The oral efficacy of Mira-55 also offers clinical convenience compared with morphine, which requires injection to achieve similar pain control.On Stocktwits, retail sentiment for Mira was ‘extremely bullish’ amid a 7,000% surge in 24-hour message volume.One user on Stocktwits called it “absolutely insane” that a small biotech like Mira could claim Mira-55 outperforms morphine, saying it could draw major investors and even qualify for FDA fast-track review. The user highlighted that Mira-55’s oral delivery and CB2 receptor action were unheard of, adding that the $60 billion+ market gives the stock huge upside potential.&nbsp;<stembedurl>https://stocktwits.com/Moobumples/message/632515002</stembedurl>Another user said he sees potential in Mira-55 becoming a “blockbuster drug” and urged others to buy.<stembedurl>https://stocktwits.com/Intradaytrade100/message/632498480</stembedurl><a href="https://stocktwits.com/symbol/MIRA">Mira Pharmaceuticals’ stock</a> has risen 16% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mira Pharmaceuticals’ stock (MIRA) has risen 16% so far in 2025. (Photo credit: Getty Images)

Mira Pharmaceuticals Stock Soars 70% After-Hours As Pain Drug Outperforms Morphine; Retail Sees ‘Blockbuster Drug’ In The Making

The company said its oral treatment fully normalized pain and sharply reduced inflammation in preclinical studies, outperforming injected morphine. 

Equity

MIRA Pharmaceuticals Inc saw its shares rise to the highest levels in nearly two months after the clinical-stage pharmaceutical company announced the board’s approval of its planned acquisition of SKNY Pharmaceuticals Inc, a deal valued at over $60 million.The acquisition, which still requires approval from MIRA and SKNY’s shareholders, has been valued based on third-party analysis conducted by Moore Financial Consulting.&nbsp;SKNY Pharmaceuticals has an enterprise value of approximately $30.5 million, while MIRA's value stands at $30 million, bringing the combined enterprise value to over $60 million.Shares of MIRA Pharmaceuticals have gained 8.7% year-to-date, closing at $1.25 on Thursday, before dipping 6.4% in after-hours trading.MIRA CEO Erez Aminov emphasized that the merger combines two robust pipelines and a unified strategy, with a focus on developing therapies for obesity and nicotine dependence.&nbsp;Under the terms of the merger, SKNY is required to hold at least $5 million in cash or other assets to be transferred at closing.&nbsp;MIRA is preparing to file with the U.S. Securities and Exchange Commission to seek shareholder approval for the deal.SKNY Pharmaceuticals’ lead compound, SKNY-1, is being developed as a next-generation oral therapeutic targeting CB1 and CB2 cannabinoid receptors, as well as monoamine oxidase B (MAO-B), which plays a key role in dopamine metabolism and addiction regulation.&nbsp;The compound is being evaluated for its potential to address both metabolic dysfunction and nicotine dependence, with applications in two high-value therapeutic areas.MIRA’s leadership views the addition of SKNY-1 to its pipeline as a key step in positioning the company to capitalize on these growing markets. Dr. Itzchak Angel, MIRA’s Chief Scientific Advisor, Itzchak Angel, said the pharmacological profile of SKNY-1 could make it an effective treatment for both addiction and metabolic disorders.&nbsp;Early data from the compound’s development has been promising, according to Angel.On Stocktwits, sentiment was described as 'bullish' amid a 1,350% surge in 24-hour message volume.&nbsp;One user noted that the merger would be a significant win, expressing confidence that shareholders from both companies would approve, while another shared frustration over a pre-market entry at $1.70, followed by an immediate pullback.<stembedurl>https://stocktwits.com/BearTamerTrading/message/613998754</stembedurl><stembedurl>https://stocktwits.com/Kc24mo/message/613981879</stembedurl>The stock has risen 8.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong

Retail sentiment on Stocktwits surged, with users expressing optimism about the merger’s success, despite a pullback in after-hours trading.

Shares of Mira Pharmaceuticals&nbsp;gained over 19% on Wednesday, marking their best session in over a month, after the company's oral ketamine analog showed promising data in a preclinical study.Mira said its Ketamir-2 therapy significantly reduced pain symptoms in rats, with some test animals returning to pre-diabetic sensitivity levels.The drug outperformed standard treatments like pregabalin and gabapentin in prior studies and has shown a favorable safety profile without ketamine's psychedelic effects, the company added.On Stocktwits, the news sent 24-hour message volume involving Mira soaring 8,500% by late Wednesday — the highest among all healthcare stocks — with sentiment turning even more 'extremely bullish.'<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/MIRA_sentiment_and_message_volume_as_of_April_16_png_9320cb3838.webp" alt="MIRA sentiment and message volume as of April 16.png" width="1318" height="316"><figcaption>MIRA sentiment and message volume as of April 16. | source: Stocktwits</figcaption></figure>One watcher expects the stock to cross the $1.2 mark on Thursday easily.<stembedurl>https://stocktwits.com/BadBritt/message/611883890</stembedurl>Another said a new 52-week high was imminent.<stembedurl>https://stocktwits.com/HMIC/message/611835137</stembedurl>Mira has already begun dosing and testing Ketamir-2 in a Phase I trial in Israel, which is expected to be completed in the fourth quarter of 2025.&nbsp;A Phase IIa trial in diabetic neuropathy is set to begin by the end of 2025, with efficacy data anticipated in early 2026.&nbsp;Mira is also developing a topical formulation for localized pain and exploring Ketamir-2's potential in PTSD treatment.Separately, Mira is progressing with its acquisition of SKNY Pharmaceuticals and sees promise in SKNY-1, a next-generation oral therapy targeting obesity and smoking cessation.Mira Pharmaceuticals' stock has lost over 8% this year but has risen nearly 29% over the past 12 months.Shares of the company fell over 11% after-hours on Wednesday, likely due to profit-taking.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mira Pharma Leads Healthcare Buzz Surge On Promising Oral Ketamine Analog Preclinical Trial

The drug outperformed standard treatments like pregabalin and gabapentin in prior studies and has shown a favorable safety profile without ketamine's psychedelic effects. 

Small-cap biotech Mira Pharmaceuticals (MIRA) has experienced a meteoric rise and subsequent plunge, captivating retail investors in the process.The company's stock surged a staggering 627% on Monday following promising preclinical data for its novel oral ketamine analog, Ketamir-2. This dramatic increase sparked a frenzy of interest, with the number of Stocktwits followers surging over 212% in just one week.Ketamir-2 has shown potential as a treatment for neurological and neuropsychiatric disorders, according to media <a href="https://www.benzinga.com/news/24/07/39885749/nano-cap-mira-pharmaceuticals-oral-ketamine-analog-shows-potential-in-neuropsychiatric-disorders?utm_source=TechInvestorNews&amp;utm_campaign=partner_feed&amp;utm_medium=partner_feed&amp;utm_content=site">reports</a>. Unlike traditional ketamine, it exhibits better oral bioavailability and appears to have a reduced risk of side effects. These advantages could position Mira as a significant player in the development of novel therapies.The company is also preparing to submit an Investigational New Drug (IND) application to the FDA by the end of this year.However, the euphoria was short-lived. The stock plummeted over 54% on Tuesday, prompting some to take profits while they still had them.Although some investors believe this represents a buying opportunity, others remain cautious, citing the long road to commercialization and the potential for future volatility.The Stocktwits stream had plenty of bearish posts, like the one from “<a href="https://stocktwits.com/Wolf_Of_Penny_Stocks/message/580409064">Wolf_of_penny_stocks</a>”, advising investors to “scalp and run” as Monday’s stock move was a “pump on preclinical data… even if they are successful it will take another 8-10 years before they generate any revenue.”<figure class="image"><img style="aspect-ratio:1320/450;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Stocktwits_user_comment_on_MIRA_stream_Jul_23_1a46479621.png" alt="Stocktwits user comment on MIRA stream Jul 23.png" width="1320" height="450"><figcaption>Stocktwits user comment on MIRA stream Jul 23</figcaption></figure>The rapid rise and fall of Mira Pharmaceuticals highlights the speculative nature of the biotech sector. While preclinical data is undoubtedly encouraging, investors must approach such volatile stocks with caution and conduct thorough due diligence before making investment decisions, as many posts on MIRA’s Stocktwits stream suggest. &nbsp;

Why Small-Cap Mira Pharma's Retail Following Has Tripled From Last Week

The tiny company's Mira Pharma stock price and Stocktwits following exploded after promising preclinical data for its novel drug, Ketamir-2.

Mira Pharma's Retail Following Has Tripled From Last Week

The tiny company's stock price and Stocktwits following exploded after promising preclinical data for its novel drug, Ketamir-2. However, a subsequent freefall has left investors wondering if this was a flash in the pan or the start of something bigger.

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. It engages in developing its product candidates, Ketamir-2 and MIRA-55, designed to address unmet medical needs in pain management, depression, PTSD, and cognitive function. The company was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.

Current Price	$1.51
Prev Close	$1.49
Open	$1.48
Dividend Yield	0.00%
50-Day Moving Average	$1.49
Beta	0.00
Avg. Volume	286,980.89
PE Ratio	-0.99

52-Week High	$2.45
52-Week Low	$0.73
Market Capitalization	$62.4M
EPS (Annual)	-$0.5085
Price to Book	7.90
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MIRA
Mira Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest MIRA News

MIRAMira Pharmaceuticals Inc